Mariacristina Parravano

Dott.ssa Mariacristina Parravano

Pubblicazioni scientifiche: PubMed

Linea di ricerca: UOS Retina Medica

Principali specializzazioni: Degenerazione maculare legata all'età, Difetti di Refrazione Oculari, Distacco di retina, Ipovisione e Riabilitazione Visiva, Occlusione Venosa Retinica, Patologia Maculare d'interesse chirurgico, Retinopatia Diabetica

Attività medica: Opera presso l'IRCCS Fondazione G.B. Bietti nelle sedi di Via Livenza, 3 e Presidio Ospedaliero Britannico di Roma.


Formazione

  • 2000 laurea in Medicina e Chirurgia nel  presso l’Università Campus Biomedico di Roma
  • 2001 Diploma di abilitazione all’esercizio professionale di medico chirurgo presso l’Università Campus Biomedico di Roma
  • 2004 specializzazione in Oftalmologia presso l’Università di Roma “Tor Vergata” nel 2004

Ruoli

  • Dal 2015 ad oggi Responsabile Unità Operativa Retina Medica Fondazione G.B. Bietti-IRCCS
  • Dal 2008 al 2014 Collaborazione coordinata e continuativa presso il Centro per le Maculopatie della Fondazione G.B.Bietti-IRCCS presso la ASL Complesso Ospedaliero S.Giovanni-Addolorata, Roma
  • Dal 2008 al 2014 Attività assistenziale presso il Centro per le Maculopatie della Fondazione G.B.Bietti-IRCCS presso la ASL Complesso Ospedaliero S.Giovanni-Addolorata, Roma
  • Dal 2004 ad oggi Ricercatrice presso il servizio di Retina Medica, Fondazione G.B.Bietti-IRCCS
  • Dal 4/4/2017 Abilitazione alle funzioni di Professore di II fascia
  • Dal 2015 ad oggi Responsabile Unità Operativa Retina Medica Fondazione G.B. Bietti-IRCCS
  • Dal 2014 ad oggi Ricercatrice di ruolo presso il servizio di Retina Medica, Fondazione G.B.Bietti-IRCCS
  • Dal 2004 al 2014 Ricercatrice a contratto presso il servizio di Retina Medica, Fondazione G.B.Bietti-IRCCS
  • Società italiana di Oftalmologia (SOI)
  • Società italiana della Retina (SIR), Consiglio direttivo dal 2015 ad oggi
  • The Association for Research in Vision and Ophthalmology (ARVO)
  • Membro Club Gonin dal 2014
  • Membro Euretina dal Settembre 2017

 

Co-Investigator in the multicentric studies

  • A six-month, phase 3, multicenter, masked, randomized, sham-controlled trial (with six-month open label extension) to assess the safety and efficacy of 700 and 350 Dexamethasone Posterior segment Drug delivery System (DEXPSDDS) Applicator System in the treatment of patients with macular edema following central retinal vein occlusion or branch vein occlusion. Study coordinator
  • A 3 year, phase 3, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 and 350 Dexamethasone Posterior Segment Drug delivery System (DEXPSDDS) Applicator System in the treatment of patients with diabetic macular edema. Study coordinator
  • A 12-month randomized, double-masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Lucentis™ monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Co-investigator
  • A 12  Months Case Series open study to assess the safety and efficacy of intravitreal injection of Lucentis(Ranibizumab 0.5 mg) used in combination with Visudyne (Verteporfin PDT) in naive subjects with subfoveal CNV secondary to AMD. Treating Investigator
  • A randomized, double masked , active controlled phase 3 study of the efficacy, safety and tolerability of repeteated doses of intravitreal VEGF trap-Eye in subjects with neovascular age-related macular degeneration (AMD) (VIEW2). Study coordinator
  • A phase II  prospective , randomised , multicentric diabetic macular edema  dose ranging, comparation study evaluating the efficacy and safety of PF- 04523655 versus laser therapy (DEGAS). Co-investigator
  • A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO) (GALILEO). Treating Investigator
  • Macular edema Incidence/Severity Reduction with NEVANAC®. Phase IIIb, prospective, multicenter, double-masked, randomized, parallel group, placebo controlled study. Study coordinator
  • Multicentric, phase 3b, randomized, single blind, controlled, 2 years follow up to evaluate the efficacy and safety of 0.5 mg ranibizumab treat and extend vs 0.5 mg ranibizumab as needed in patients with diabetic macular edema (RETAIN). Treating investigator
  • Multicentric, phase 3, randomized, double blind, active control, 12 months follow up to evaluate the efficacy and safety of 0.5 mg ranibizumab vs photodynamic therapy in myopic CNV. Treating investigator
  • A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema (VIVID). Study coordinator
  • A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex® Versus Lucentis® in Patients with Branch Retinal Vein Occlusion (COMO). Study coordinator
  • A multicenter, open-label, randomized study comparing the efficacy and safety of 700 mg Dexamethasone posterior segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema. Study coordinator.
  • A non-interventional study in patients with diabetic macula edema (DME) with central involvement to assess the effectiveness of existing anti vascular endothelial growth factor (anti-VEGF) treatment regimens (POLARIS). Bayer. Sub-Investigator.
  • Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy. (PROTEUS). Sub-Investigator.
  • A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV) (MINERVA). Novartis. Sub-Investigator.
  • A 12 months, open-label, interventional, multicentre study to investigate the current criteria driving re-treatment with ranibizumab upon relapse in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia. Novartis. Sub-Investigator.
  • A 12-month, phase IIIb, randomized, single-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in Treat and Extend regimen compared to Monthly regimen, in patients with neovascular agerelated macular degeneration (TREND). Novartis. Sub-Investigator.
  • A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration (FOVISTA). Ophthotec. Study Coordinator.
  • A Collaborative Retrospective Trial on the Efficacy and Safety of intravitreal dexamethasone implant (Ozurdex) in patients with Diabetic Macular Edema (DME). THE EUROPEAN DME REGISTRAR STUDY (ARTES). Allergan. Follow up investigator.

Principal Investigator in the multicentric studies

  • Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration (DARPin) Allergan.
  • A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY OF EFFICACY AND SAFETY OF 10 mg LAMPALIZUMAB INTRAVITREAL INJECTIONS ADMINISTERED EVERY 30 OR 45 DAYS TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. ROCHE.
  • Acta Ophthalmologica
  • Plosone
  • IOVS
  • BJO
  • Acta Diabetologica
  • Cochrane systemic revision
  • Ophthalmologica
  • AJO
  • Retina

Parte dell’Editorial Board: Italian Review of Ophthalmology
Ophthalmology @ Point of Care

 

  • Vincitrice 2003 ARVO Travel Grant Fondazione GB Bietti per lo studio e la ricerca in Oftalmologia.
  • Vincitrice del premio “Associazione Amici di Vanda” per la ricerca 2009 presso Congresso Givre, Varese 19 Giugno 2009.
  • Conto Capitale 2015 Ministero della Salute “"Analisi multimodale morfo-funzionale wide-field per lo studio neuro-vascolare delle patologie neuro-retiniche ad alto impatto sociale"